All Outputs (2)

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial (2013)
Journal Article
Ford, H., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F., Wadsley, J., …Dunn, J. A. (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology, 15(1), https://doi.org/10.1016/S1470-2045%2813%2970549-7

BACKGROUND: Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to act... Read More about Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas (2013)
Journal Article
Storr, S. J., Pu, X., Davis, J., Lobo, D., Reece-Smith, A. M., Parsons, S. L., …Martin, S. G. (2013). Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. Journal of Gastroenterology, 48(11), 1213-1221. https://doi.org/10.1007/s00535-012-0743-4